European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- -

The monograph outlines a suite of tests to ensure quality and performance. These tests are performed on a sample of the batch.

| Feature | Ph. Eur. 0478 | USP <701> / <711> | JP (Tablets) | |---------|---------------|--------------------|---------------| | Scope | Uncoated & film-coated only | Includes chewable, buccal, etc. | Broader – includes effervescent | | Dissolution | 2.9.3 with Q-value | <711> with S1, S2, S3 stages | Similar to USP | | Disintegration | Permitted as alternative | Not a substitute for dissolution (except BCS Class I or III) | Permitted | | Friability | Optional unless specified | Mandatory (USP <1216>) | Mandatory | | Hardness | Not required | Not required but common | Not required |

This test measures the tablet's ability to withstand abrasion during packaging and transport. A sample of tablets is rotated in a drum for a set time (usually 100 rotations). European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Monograph 0478 does not specify which chemical identity test to use (that is left to the individual active substance monograph). However, it mandates that the identification tests for the active substance(s) must be capable of distinguishing the tablet from placebo.

Practical implications for QC labs:

Most manufacturers reference Ph. Eur. 2.9.40 (Uniformity of Dosage Units) as part of the identification strategy, ensuring the correct label claim is present in the correct proportion.

Monograph 0478 classifies tablets based on their release characteristics and site of action: The monograph outlines a suite of tests to

The label must clearly state:

If the tablet is scored (has a line to facilitate breaking), the label should indicate whether the tablet is suitable for division to obtain a specific dose. Most manufacturers reference Ph